Literature DB >> 35294602

Supplementation of PQQ from pregnancy prevents MK-801-induced schizophrenia-like behaviors in mice.

Ying Peng1,2, Dong Xu3, Yuedi Ding3, Xingqin Zhou4.   

Abstract

RATIONALE: At present, the research on the prevention of schizophrenia is still in its infancy. Pyrroloquinoline quinone (PQQ) has potential to treat psychological and neurological diseases including schizophrenia. However, the preventive effect of PQQ on schizophrenia remains unclear.
OBJECTIVES: In this study, we aimed to examine the preventive effect of supplementation of dietary PQQ from pregnancy or after birth on dizocilpine (MK-801)-induced schizophrenia-like behaviors in mice.
RESULTS: Supplementation of dietary PQQ from pregnancy could effectively prevent MK-801-induced weight gain decrease, hyperlocomotion, stereotypical behavior, ataxia, exploratory activity decrease, social interaction disorder, memory deficit, and depression in mice. Supplementation of dietary PQQ after birth could effectively prevent MK-801-induced weight gain decrease, stereotypical behavior, ataxia, and memory deficit in mice. Female mice responded to a greater degree than males in preventing MK-801-induced weight gain decrease in both forms of PQQ supplementation. For mice that began PQQ supplementation after birth, females performed better than males in preventing MK-801-induced ataxia, memory deficit, and depression. For mice that began PQQ supplementation from pregnancy, males performed better than females in preventing MK-801-induced memory deficit. In vitro experiments indicated that PQQ supplementation in the earlier stage of life contributed to the growth of neurons and the development of neurites.
CONCLUSIONS: Our current study suggested that PQQ supplementation from pregnancy or postpartum could prevent some schizophrenia-like behaviors induced by MK-801 in mice. Our work supported the potential usage of dietary supplement of PQQ in preventing or alleviating symptoms associated with schizophrenia.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  MK-801; NMDA receptor; Prevention; Pyrroloquinoline quinone; Schizophrenia

Mesh:

Substances:

Year:  2022        PMID: 35294602     DOI: 10.1007/s00213-022-06113-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  60 in total

1.  Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice.

Authors:  R V de Oliveira; O P Dall'Igna; A B L Tort; J F Schuh; P F Neto; M W Santos Gomes; D O Souza; D R Lara
Journal:  Behav Pharmacol       Date:  2005-03       Impact factor: 2.293

2.  The Economic Burden of Schizophrenia in the United States in 2013.

Authors:  Martin Cloutier; Myrlene Sanon Aigbogun; Annie Guerin; Roy Nitulescu; Agnihotram V Ramanakumar; Siddhesh A Kamat; Michael DeLucia; Ruth Duffy; Susan N Legacy; Crystal Henderson; Clement Francois; Eric Wu
Journal:  J Clin Psychiatry       Date:  2016-06       Impact factor: 4.384

3.  Further evidence that pyrroloquinoline quinone interacts with the N-methyl-D-aspartate receptor redox site in rat cortical neurons in vitro.

Authors:  E Aizenman; F E Jensen; P M Gallop; P A Rosenberg; L H Tang
Journal:  Neurosci Lett       Date:  1994-02-28       Impact factor: 3.046

Review 4.  NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update.

Authors:  Daniela Cadinu; Ben Grayson; Giovanni Podda; Michael K Harte; Nazanin Doostdar; Joanna C Neill
Journal:  Neuropharmacology       Date:  2017-11-28       Impact factor: 5.250

Review 5.  Pyrroloquinoline quinone: a novel vitamin?

Authors:  A Bishop; P M Gallop; M L Karnovsky
Journal:  Nutr Rev       Date:  1998-10       Impact factor: 7.110

6.  Interaction of the putative essential nutrient pyrroloquinoline quinone with the N-methyl-D-aspartate receptor redox modulatory site.

Authors:  E Aizenman; K A Hartnett; C Zhong; P M Gallop; P A Rosenberg
Journal:  J Neurosci       Date:  1992-06       Impact factor: 6.167

7.  Nuclear respiratory factor 1 (NRF-1) upregulates the expression and function of reduced folate carrier (RFC) at the blood-brain barrier.

Authors:  Camille Alam; Md Tozammel Hoque; Vishal Sangha; Reina Bendayan
Journal:  FASEB J       Date:  2020-06-16       Impact factor: 5.191

8.  Dermatoglyphics and Schizophrenia: a meta-analysis and investigation of the impact of obstetric complications upon a-b ridge count.

Authors:  Elvira Bramon; Muriel Walshe; Colm McDonald; Beatriz Martín; Timothea Toulopoulou; Harvey Wickham; Jim van Os; Paul Fearon; Pak C Sham; Lourdes Fañanás; Robin M Murray
Journal:  Schizophr Res       Date:  2005-06-15       Impact factor: 4.939

9.  A plausible model of schizophrenia must incorporate psychological and social, as well as neuro developmental, risk factors.

Authors:  E Bramon; R M Murray
Journal:  Dialogues Clin Neurosci       Date:  2001-12       Impact factor: 5.986

Review 10.  Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment.

Authors:  Christoph U Correll; Nina R Schooler
Journal:  Neuropsychiatr Dis Treat       Date:  2020-02-21       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.